TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia

TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia

Cytokine receptor-like factor 2 B-cell acute lymphoblastic leukemia (CRLF2 B-ALL) is a high-risk subtype characterized by CRLF2 overexpression with poor survival rates in children and adults. CRLF2 and interleukin-7 receptor alpha (IL-7Rα) form a receptor for the cytokine thymic stromal lymphopoieti...

Full description

Bibliographic Details
Main Authors: Hossam R. Alkashgari, Caleb Ruiz-Jimenez, Cornelia Stoian, Jacqueline S. Coats, Ineavely Baez, Evgeny Chirshev, Shannalee R. Martinez, Sinisa Dovat, Olivia L. Francis-Boyle, Carlos A. Casiano, Kimberly J. Payne
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Molecular Sciences
Subjects:
TSLP
CRLF2
B-ALL
IL-7Rα
SOCS
apoptosis
Online Access:https://www.mdpi.com/1422-0067/24/1/474

Internet

https://www.mdpi.com/1422-0067/24/1/474

Similar Items